Developer docs
API playgroundTry for free, no card

Search company profiles

Brainomix

Full company profile

uuid000087y

Namestring
Brainomix
Legal namestring
Brainomix Limited
Websiteurl
brainomix.com
Company typeenum
Private
Founded yearint
2010
Descriptiontext

Brainomix is a UK-based medical imaging software company founded in 2010 as a spinout from the University of Oxford. It develops AI-powered imaging biomarkers that automate the interpretation of CT, CTA, CTP, and MRI brain and lung scans, with a primary focus on acute stroke assessment and an expanding portfolio in pulmonary fibrosis and oncology. The company's flagship platform, Brainomix 360 Stroke, integrates modules (e-ASPECTS, e-CTA, e-CTP, e-MRI, Triage Stroke, Triage LVO) that score ASPECTS, detect large vessel occlusions, quantify perfusion cores and penumbra, and deliver real-time smartphone alerts to clinicians. The platform is FDA-cleared and CE-marked as a Class IIa medical device, and the company has also received FDA clearance for its e-Lung module targeting progressive pulmonary fibrosis and has begun positioning Brainomix 360 Cancer for solid tumor assessment.

The company generates revenue through enterprise software licensing to hospitals and healthcare systems on multi-year subscription contracts, complemented by professional services for clinical trial imaging analysis supplied to pharmaceutical sponsors. Pricing is quote-based with modules sold individually or bundled. Distribution combines a direct enterprise sales force (with dedicated Sales Directors for EMEA and US regions) and channel partnerships with major neurovascular device companies including Medtronic, Stryker Neurovascular, 3DR Labs, Blackford, and Calantic Digital Solutions. Reported scale metrics include deployments across 30+ countries, 100+ NHS hospitals in England, 2 million+ cumulative scans processed, a scan rate of one patient every three minutes, and 56+ peer-reviewed clinical publications, including the largest real-world stroke AI evaluation (450,000+ patients across 107 hospitals) published in The Lancet Digital Health.

Short descriptiontext

Brainomix is a UK-based AI medical imaging company developing FDA-cleared imaging biomarkers for stroke, lung fibrosis, and cancer. Founded in 2010 as a University of Oxford spinout, it serves hospitals, healthcare systems, and pharmaceutical companies across 30+ countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersOxford, United Kingdom
HQ citystring
Oxford
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI medical imaging, stroke imaging software, lung fibrosis detection, clinical decision support, imaging biomarker analysis
Industry4 codes
PRIMARYHDAAAEAH
Medical Imaging AI
SECONDARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLAGAEAH
Imaging Core Labs & Clinical Endpoint Adjudication
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
NAICS code1 code
  • Other Scientific and Technical Consulting Services54169
SIC code2 codes
  • Services-Prepackaged Software7372
  • Surgical & Medical Instruments & Apparatus3841
Product category
AI Medical Imaging Software
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Healthcare Software Licensing
TypeSubscription Recurring
Description

Brainomix 360 Stroke and e-Lung platforms licensed to hospitals as medical devices with modules (e-ASPECTS, e-CTA, e-CTP) available separately or as integrated packages. Licensed as CE-marked Class IIa medical devices for clinical decision support.

brainomix.com
2Clinical Trial Imaging Services
TypeProfessional Services
Description

Quantitative imaging biomarker analysis and Core Lab analytics services for pharmaceutical clinical trials. Supports patient selection, endpoint assessment, and retrospective analysis for stroke, lung fibrosis, and oncology studies.

brainomix.com
3Professional Services & Training
TypeProfessional Services
Description

Implementation, training, and customer support services with 24/7 SLA support, on-site training, and customization services for hospital integration.

brainomix.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
Pricing details1 tier
1Enterprise hospital licensing with modular options
ModelSubscriptionBilling cadenceMulti-year contract
Notes

Individual modules (e-ASPECTS, e-CTA, e-CTP) can be licensed separately or as a package. Enterprise licensing for hospital networks with dedicated support.

brainomix.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 9 records shown
1Brainomix 360 Stroke
Description

Comprehensive AI-powered stroke imaging platform providing decision support for acute stroke assessment, including e-ASPECTS, e-CTA, e-CTP, e-MRI modules.

brainomix.com
+8 more records
Core offering1 text field

Brainomix develops and sells AI-powered medical imaging software (the Brainomix 360 platform) that automates analysis of CT, CTA, CTP, and MRI scans for acute stroke assessment, pulmonary fibrosis detection, and solid tumor evaluation. The software is licensed to hospitals and healthcare systems as CE-marked Class IIa and FDA-cleared medical devices, with separate modules (e-ASPECTS, e-CTA, e-CTP, e-MRI, Triage Stroke, Triage LVO) available individually or as integrated packages. The company also provides clinical trial imaging biomarker services and Core Lab analytics to pharmaceutical companies for drug development.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 100% relative increase in mechanical thrombectomy rates across NHS hospitals in England using Brainomix 360 Stroke
+5 more records
Product overview1 text field

Brainomix offers the Brainomix 360 platform, a comprehensive AI-powered imaging solution with multiple integrated modules. The platform comprises Brainomix 360 Stroke (the core stroke imaging platform) with add-on modules including e-ASPECTS for NCCT analysis, e-CTA for CTA/LVO detection, e-CTP for perfusion analysis, e-MRI for advanced MRI assessment, Triage Stroke for ICH notification, and Triage LVO for LVO alerts. The platform also extends to e-Lung for pulmonary fibrosis CT analysis and Brainomix 360 Cancer for tumor assessment in clinical trials. Results are delivered via PACS integration, email notifications, mobile apps (iOS/Android), and web browser interface.

Product and service4 records
1Brainomix 360 Stroke
CategoryStroke Imaging Software Platform
Description

Comprehensive FDA-cleared and CE-marked AI imaging platform for acute stroke assessment, supporting automated analysis of non-contrast CT, CTA, CTP, and MRI images across the full stroke pathway from diagnosis to treatment decisions. Includes modules for ASPECTS scoring (e-ASPECTS), LVO detection (e-CTA), perfusion analysis (e-CTP), MRI analysis (e-MRI), and real-time triage notifications (Triage Stroke, Triage LVO). Licensed to hospitals and healthcare systems as CE-marked Class IIa medical devices.

2e-Lung
CategoryLung Imaging Software
Description

FDA-cleared AI-powered imaging software platform that automatically identifies and quantifies features on CT lung scans to detect progressive pulmonary fibrosis (PPF). Enables clinicians to identify subtle deteriorations over multiple scan timepoints, supporting earlier diagnosis and treatment decisions for pulmonary fibrosis patients. Deployed through partnership with Boehringer Ingelheim.

3Brainomix 360 Cancer
CategoryOncology Imaging Software
Description

AI-powered solution for assessment of solid tumors, characterizing and quantifying tumors using imaging biomarkers. Available for use in clinical trials to support efficacy detection and Blinded Independent Central Review (BICR). Developed in collaboration with pharma partners for oncology drug development.

4Life Sciences Imaging Biomarker Services
CategoryClinical Trial Services
Description

AI-powered quantitative imaging biomarkers and regulated software services for pharmaceutical and biotech clinical trials. Includes retrospective analysis, prospective trial support, real-world validation, and bespoke digital biomarker development. Supports patient selection, endpoint assessment, and efficacy detection for pharma sponsors across stroke, pulmonary fibrosis, and oncology indications. Provided through direct engagement with pharma companies and CRO partnerships.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership22 partners
1Boehringer Ingelheim
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-05-12
Description

Expanded strategic partnership to advance clinical deployment of e-Lung, FDA-cleared AI-powered imaging platform for detecting progressive pulmonary fibrosis. Next phase PROGRESS-PPF is a prospective multicenter study across US sites generating real-world evidence. Prior REVISE-PPF retrospective study demonstrated e-Lung could identify PPF up to 28 months earlier than clinical diagnoses. Also collaborated on INBUILD Phase III trial validation.

prnewswire.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-18
Description

Partnership to analyze Phase II clinical trial data for ARG-007 neuroprotective drug for acute ischemic stroke. Brainomix AI-powered imaging analysis confirmed statistically significant efficacy in patients with large strokes, demonstrating improved neurological outcomes and smaller infarct volumes.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-06-24
Description

Strategic partnership to support acute stroke care in US through clinically validated and FDA-cleared Brainomix 360 Stroke imaging solution. 3DR Labs is market leader in medical imaging post-processing services.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-03-26
Description

International research collaboration validating significance of Brainomix's follow-up infarct volume (FIV) automated imaging biomarkers to predict clinical outcomes after acute ischemic stroke. Published in Frontiers in Neurology.

Strategic tierFlagshipTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-02-27
Description

Collaboration between leading stroke AI imaging partner and leading neurovascular device provider to enhance stroke care, expand access to life-changing treatments, and improve patient outcomes.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-10-09
Description

AI-assisted robotic system development for remote stroke intervention. Swiss-based Nanoflex received Innosuisse grant with Brainomix as UK collaborator for AI-powered remote diagnosis and treatment platform starting 2024. Project aims to develop AI-assisted magnetic navigation system for robotic surgical tools.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership to analyze Phase 2 tralokinumab clinical trial data using Brainomix AI-powered software and biomarkers to uncover novel insights in interstitial lung disease. Published in AJRCCM.

8Bridge Biotherapeutics
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partnership on BBT-877 (NCT05483907) study assessing treatment effect in IPF. Brainomix technology and AI imaging biomarkers providing deep data analytics to enrich clinical development.

brainomix.com
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Exclusive distribution partnership for Pixyl.Neuro.MS Software as a Service solution in UK, Ireland, Nordics, and key Eastern Europe markets for multiple sclerosis imaging.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Partnership to expand access to life-saving stroke treatments by combining Stryker's neurovascular devices with Brainomix AI imaging for improved stroke network care.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

AI partnership for stroke care increasing access to advanced AI-assisted stroke care through Blackford's platform distribution.

12OSIC (Open Source Imaging Consortium)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Founder member of consortium connecting academia, industry, and philanthropy in fight against lung disease. Collaborating on e-ILD platform development.

nanoflexrobotics.com
13NCIMI (National Consortium of Intelligent Medical Imaging)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

UK government-funded collaboration evaluating AI-powered technology in lung cancer care. Brainomix e-ACT for automated assessment of disease progression and treatment response.

nanoflexrobotics.com
Strategic tierFlagshipTypeGTM or Marketing Partner
Description

Proud partner alongside WSO and ESO. Initiative built global community of 5,000+ hospitals to increase patients treated in stroke ready hospitals and optimize treatment quality.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration assessing Brainomix novel IPF biomarker in lung disease. e-Lung CT scanning technology integrated into TIPAL study for interstitial lung abnormalities.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Channel partnership for distribution of stroke AI solutions in target markets.

17Calantic Digital Solutions
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Distribution partnership for AI imaging solutions in digital health markets.

nanoflexrobotics.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Oxford-based local enterprise partnership supporting innovation and growth in Oxford region.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Channel partnership for stroke AI solution distribution.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Post-hoc assessment of ACTIMIS study results using Brainomix AI software to reinforce glenzocimab's mode of action in stroke patients.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Life sciences partnership for stroke therapy clinical development.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Life sciences partnership for AI-enhanced clinical trial solutions.

Recent move10 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Direct competitor selling FDA-cleared AI modules for ASPECTS scoring, CT perfusion, and LVO detection, with deep US hospital penetration — the closest direct peer to Brainomix 360 Stroke.

TypeDirect peer
Description

Direct competitor focused on LVO/ICH triage and care coordination, also expanding into cardiology and other specialties; competes head-to-head in US stroke networks for AI imaging and workflow.

3Avicenna.AI
TypeDirect peer
Description

Direct peer offering AI tools for stroke and broader CT triage, with FDA-cleared modules for LVO, ICH, and PE — overlapping product footprint and similar hospital GTM.

TypeDirect peer
Description

Europe-based direct peer with StrokeViewer, a CE-marked AI suite for ASPECTS, LVO, and perfusion analysis; comparable in stroke-only focus and European hospital customer base.

TypeDirect peer
Description

Direct peer providing RAPID software for CT/MR perfusion and ASPECTS used widely in stroke trials and clinical practice; significant overlap with Brainomix's clinical-trial imaging services and stroke modules.

TypeEmerging player
Description

Broader AI imaging vendor with FDA-cleared triage across multiple body parts; partial overlap via ICH/LVO detection and competes for the same radiology AI budget, though its portfolio is wider than stroke.

TypeEmerging player
Description

AI imaging company with FDA/CE-cleared modules for head CT (ICH, stroke, midline shift) and chest X-ray/tuberculosis; comparable in head CT triage and emerging-market deployment model.

TypeEmerging player
Description

Brain MRI AI vendor with FDA-cleared and CE-marked modules for multiple sclerosis and dementia; adjacent neuro-imaging focus with similar clinical evidence-based GTM and pharma services motion.

TypeEmerging player
Description

AI vendor specializing in chest CT and X-ray, including ClearRead CT for lung nodule and fibrosis detection; overlaps with Brainomix e-Lung in lung imaging AI.

10Nanox
TypeBroad incumbent
Description

Broad medical imaging and AI platform (incorporating Zebra Medical Vision assets) selling multi-disease AI algorithms including stroke and lung; broader and less specialized than Brainomix but addresses the same hospital customers.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers9 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration4 records

Each record includes

Title, Type, Description, Source

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature9 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles17 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Brainomix

AI Medical Imaging Softwarebrainomix.com

Brainomix is a UK-based AI medical imaging company developing FDA-cleared imaging biomarkers for stroke, lung fibrosis, and cancer. Founded in 2010 as a University of Oxford spinout, it serves hospitals, healthcare systems, and pharmaceutical companies across 30+ countries.

What Brainomix does

Brainomix is a UK-based medical imaging software company founded in 2010 as a spinout from the University of Oxford. It develops AI-powered imaging biomarkers that automate the interpretation of CT, CTA, CTP, and MRI brain and lung scans, with a primary focus on acute stroke assessment and an expanding portfolio in pulmonary fibrosis and oncology. The company's flagship platform, Brainomix 360 Stroke, integrates modules (e-ASPECTS, e-CTA, e-CTP, e-MRI, Triage Stroke, Triage LVO) that score ASPECTS, detect large vessel occlusions, quantify perfusion cores and penumbra, and deliver real-time smartphone alerts to clinicians. The platform is FDA-cleared and CE-marked as a Class IIa medical device, and the company has also received FDA clearance for its e-Lung module targeting progressive pulmonary fibrosis and has begun positioning Brainomix 360 Cancer for solid tumor assessment.

The company generates revenue through enterprise software licensing to hospitals and healthcare systems on multi-year subscription contracts, complemented by professional services for clinical trial imaging analysis supplied to pharmaceutical sponsors. Pricing is quote-based with modules sold individually or bundled. Distribution combines a direct enterprise sales force (with dedicated Sales Directors for EMEA and US regions) and channel partnerships with major neurovascular device companies including Medtronic, Stryker Neurovascular, 3DR Labs, Blackford, and Calantic Digital Solutions. Reported scale metrics include deployments across 30+ countries, 100+ NHS hospitals in England, 2 million+ cumulative scans processed, a scan rate of one patient every three minutes, and 56+ peer-reviewed clinical publications, including the largest real-world stroke AI evaluation (450,000+ patients across 107 hospitals) published in The Lancet Digital Health.

Brainomix firmographics

Firmographics
Name
Brainomix
Legal name
Brainomix Limited
Website
https://brainomix.com
Company type
Private
Founded year
2010
Operating status
Operating
Headcount range
51–100 employees
Short description
Brainomix is a UK-based AI medical imaging company developing FDA-cleared imaging biomarkers for stroke, lung fibrosis, and cancer. Founded in 2010 as a University of Oxford spinout, it serves hospitals, healthcare systems, and pharmaceutical companies across 30+ countries.
Ownership category
akta.pro rank

Brainomix industry classification

Industry
Product category
AI Medical Imaging Software
NAICS
Other Scientific and Technical Consulting Services (54169)
SIC
Services-Prepackaged Software (7372), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHDAAAEAH
Medical Imaging AI
SECONDARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLAGAEAH
Imaging Core Labs & Clinical Endpoint Adjudication
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)

Keywords

  • AI medical imaging
  • Stroke imaging software
  • Lung fibrosis detection
  • Clinical decision support
  • Imaging biomarker analysis

Where Brainomix is headquartered

Location

Headquarters

HQ city
Oxford
HQ country
United Kingdom
HQ region
Europe

Offices3 records

Markets served

Brainomix business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Healthcare Software Licensing: Brainomix 360 Stroke and e-Lung platforms licensed to hospitals as medical devices with modules (e-ASPECTS, e-CTA, e-CTP) available separately or as integrated packages. Licensed as CE-marked Class IIa medical devices for clinical decision support.
  2. Clinical Trial Imaging Services: Quantitative imaging biomarker analysis and Core Lab analytics services for pharmaceutical clinical trials. Supports patient selection, endpoint assessment, and retrospective analysis for stroke, lung fibrosis, and oncology studies.
  3. Professional Services & Training: Implementation, training, and customer support services with 24/7 SLA support, on-site training, and customization services for hospital integration.

Pricing tiers

ModelBillingPrice
SubscriptionMulti-year contractEnterprise hospital licensing with modular options

Go-to-market motion3 records

Distribution channels4 records

Marketing channels7 records

Brainomix product offering

Product offering

Core offering

Brainomix develops and sells AI-powered medical imaging software (the Brainomix 360 platform) that automates analysis of CT, CTA, CTP, and MRI scans for acute stroke assessment, pulmonary fibrosis detection, and solid tumor evaluation. The software is licensed to hospitals and healthcare systems as CE-marked Class IIa and FDA-cleared medical devices, with separate modules (e-ASPECTS, e-CTA, e-CTP, e-MRI, Triage Stroke, Triage LVO) available individually or as integrated packages. The company also provides clinical trial imaging biomarker services and Core Lab analytics to pharmaceutical companies for drug development.

Product overview

Brainomix offers the Brainomix 360 platform, a comprehensive AI-powered imaging solution with multiple integrated modules. The platform comprises Brainomix 360 Stroke (the core stroke imaging platform) with add-on modules including e-ASPECTS for NCCT analysis, e-CTA for CTA/LVO detection, e-CTP for perfusion analysis, e-MRI for advanced MRI assessment, Triage Stroke for ICH notification, and Triage LVO for LVO alerts. The platform also extends to e-Lung for pulmonary fibrosis CT analysis and Brainomix 360 Cancer for tumor assessment in clinical trials. Results are delivered via PACS integration, email notifications, mobile apps (iOS/Android), and web browser interface.

Differentiator

Problem solved

Functional benefit

Brands

  • Brainomix 360 Stroke: Comprehensive AI-powered stroke imaging platform providing decision support for acute stroke assessment, including e-ASPECTS, e-CTA, e-CTP, e-MRI modules.
  • e-Lung
  • Brainomix 360 Cancer
  • e-ASPECTS
  • e-CTA
  • e-CTP
  • e-MRI
  • Triage Stroke
  • Triage LVO

Products and services

  • Brainomix 360 Stroke Comprehensive FDA-cleared and CE-marked AI imaging platform for acute stroke assessment, supporting automated analysis of non-contrast CT, CTA, CTP, and MRI images across the full stroke pathway from diagnosis to treatment decisions. Includes modules for ASPECTS scoring (e-ASPECTS), LVO detection (e-CTA), perfusion analysis (e-CTP), MRI analysis (e-MRI), and real-time triage notifications (Triage Stroke, Triage LVO). Licensed to hospitals and healthcare systems as CE-marked Class IIa medical devices.
  • e-Lung FDA-cleared AI-powered imaging software platform that automatically identifies and quantifies features on CT lung scans to detect progressive pulmonary fibrosis (PPF). Enables clinicians to identify subtle deteriorations over multiple scan timepoints, supporting earlier diagnosis and treatment decisions for pulmonary fibrosis patients. Deployed through partnership with Boehringer Ingelheim.
  • Brainomix 360 Cancer AI-powered solution for assessment of solid tumors, characterizing and quantifying tumors using imaging biomarkers. Available for use in clinical trials to support efficacy detection and Blinded Independent Central Review (BICR). Developed in collaboration with pharma partners for oncology drug development.
  • Life Sciences Imaging Biomarker Services AI-powered quantitative imaging biomarkers and regulated software services for pharmaceutical and biotech clinical trials. Includes retrospective analysis, prospective trial support, real-world validation, and bespoke digital biomarker development. Supports patient selection, endpoint assessment, and efficacy detection for pharma sponsors across stroke, pulmonary fibrosis, and oncology indications. Provided through direct engagement with pharma companies and CRO partnerships.

Quantifiable outcome

  • 100% relative increase in mechanical thrombectomy rates across NHS hospitals in England using Brainomix 360 Stroke
  • +5 more outcomes

Companies that use Brainomix

Customer profile

Named customers9 records

Segments3 records

Ideal customer profiles2 records

Brainomix technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability3 records

Feature9 records

Brainomix partnerships and signals

Strategic signal

Partnerships

22 partnerships are on record, tiered flagship, core and minor.

  • Boehringer IngelheimflagshipStrategic or Co-development Partner · 12 May 2026Expanded strategic partnership to advance clinical deployment of e-Lung, FDA-cleared AI-powered imaging platform for detecting progressive pulmonary fibrosis. Next phase PROGRESS-PPF is a prospective multicenter study across US sites generating real-world evidence. Prior REVISE-PPF retrospective study demonstrated e-Lung could identify PPF up to 28 months earlier than clinical diagnoses. Also collaborated on INBUILD Phase III trial validation.
  • Argenica TherapeuticscoreStrategic or Co-development Partner · 18 December 2025Partnership to analyze Phase II clinical trial data for ARG-007 neuroprotective drug for acute ischemic stroke. Brainomix AI-powered imaging analysis confirmed statistically significant efficacy in patients with large strokes, demonstrating improved neurological outcomes and smaller infarct volumes.
  • 3DR LabscoreChannel Partner/ Reseller/ Distributor · 24 June 2025Strategic partnership to support acute stroke care in US through clinically validated and FDA-cleared Brainomix 360 Stroke imaging solution. 3DR Labs is market leader in medical imaging post-processing services.
  • CSLcoreStrategic or Co-development Partner · 26 March 2025International research collaboration validating significance of Brainomix's follow-up infarct volume (FIV) automated imaging biomarkers to predict clinical outcomes after acute ischemic stroke. Published in Frontiers in Neurology.
  • MedtronicflagshipChannel Partner/ Reseller/ Distributor · 27 February 2025Collaboration between leading stroke AI imaging partner and leading neurovascular device provider to enhance stroke care, expand access to life-changing treatments, and improve patient outcomes.
  • Nanoflex RoboticscoreStrategic or Co-development Partner · 9 October 2023AI-assisted robotic system development for remote stroke intervention. Swiss-based Nanoflex received Innosuisse grant with Brainomix as UK collaborator for AI-powered remote diagnosis and treatment platform starting 2024. Project aims to develop AI-assisted magnetic navigation system for robotic surgical tools.
  • AstraZenecacoreStrategic or Co-development PartnerPartnership to analyze Phase 2 tralokinumab clinical trial data using Brainomix AI-powered software and biomarkers to uncover novel insights in interstitial lung disease. Published in AJRCCM.
  • Bridge BiotherapeuticsminorStrategic or Co-development PartnerPartnership on BBT-877 (NCT05483907) study assessing treatment effect in IPF. Brainomix technology and AI imaging biomarkers providing deep data analytics to enrich clinical development.
  • PixylminorChannel Partner/ Reseller/ DistributorExclusive distribution partnership for Pixyl.Neuro.MS Software as a Service solution in UK, Ireland, Nordics, and key Eastern Europe markets for multiple sclerosis imaging.
  • Stryker NeurovascularcoreChannel Partner/ Reseller/ DistributorPartnership to expand access to life-saving stroke treatments by combining Stryker's neurovascular devices with Brainomix AI imaging for improved stroke network care.
  • BlackfordminorChannel Partner/ Reseller/ DistributorAI partnership for stroke care increasing access to advanced AI-assisted stroke care through Blackford's platform distribution.
  • OSIC (Open Source Imaging Consortium)minorStrategic or Co-development PartnerFounder member of consortium connecting academia, industry, and philanthropy in fight against lung disease. Collaborating on e-ILD platform development.
  • NCIMI (National Consortium of Intelligent Medical Imaging)minorStrategic or Co-development PartnerUK government-funded collaboration evaluating AI-powered technology in lung cancer care. Brainomix e-ACT for automated assessment of disease progression and treatment response.
  • Angels InitiativeflagshipGTM or Marketing PartnerProud partner alongside WSO and ESO. Initiative built global community of 5,000+ hospitals to increase patients treated in stroke ready hospitals and optimize treatment quality.
  • TIPAL TrialminorStrategic or Co-development PartnerCollaboration assessing Brainomix novel IPF biomarker in lung disease. e-Lung CT scanning technology integrated into TIPAL study for interstitial lung abnormalities.
  • Wallaby MedicalminorChannel Partner/ Reseller/ DistributorChannel partnership for distribution of stroke AI solutions in target markets.
  • Calantic Digital SolutionsminorChannel Partner/ Reseller/ DistributorDistribution partnership for AI imaging solutions in digital health markets.
  • OxLEPminorStrategic or Co-development PartnerOxford-based local enterprise partnership supporting innovation and growth in Oxford region.
  • ForaminorChannel Partner/ Reseller/ DistributorChannel partnership for stroke AI solution distribution.
  • Acticor BiotechminorStrategic or Co-development PartnerPost-hoc assessment of ACTIMIS study results using Brainomix AI software to reinforce glenzocimab's mode of action in stroke patients.
  • LumosaminorStrategic or Co-development PartnerLife sciences partnership for stroke therapy clinical development.
  • Remedy PartnersminorStrategic or Co-development PartnerLife sciences partnership for AI-enhanced clinical trial solutions.

Scale indicators12 records

Recent moves10 records

Expansion highlights7 records

Brainomix competitors and assessment

Company assessment

Direct peers

  • RapidAI: Direct competitor selling FDA-cleared AI modules for ASPECTS scoring, CT perfusion, and LVO detection, with deep US hospital penetration — the closest direct peer to Brainomix 360 Stroke.
  • Viz.ai: Direct competitor focused on LVO/ICH triage and care coordination, also expanding into cardiology and other specialties; competes head-to-head in US stroke networks for AI imaging and workflow.
  • Avicenna.AI: Direct peer offering AI tools for stroke and broader CT triage, with FDA-cleared modules for LVO, ICH, and PE — overlapping product footprint and similar hospital GTM.
  • Nico.lab: Europe-based direct peer with StrokeViewer, a CE-marked AI suite for ASPECTS, LVO, and perfusion analysis; comparable in stroke-only focus and European hospital customer base.
  • Ischemaview: Direct peer providing RAPID software for CT/MR perfusion and ASPECTS used widely in stroke trials and clinical practice; significant overlap with Brainomix's clinical-trial imaging services and stroke modules.

Emerging players

  • Aidoc: Broader AI imaging vendor with FDA-cleared triage across multiple body parts; partial overlap via ICH/LVO detection and competes for the same radiology AI budget, though its portfolio is wider than stroke.
  • Qure.ai: AI imaging company with FDA/CE-cleared modules for head CT (ICH, stroke, midline shift) and chest X-ray/tuberculosis; comparable in head CT triage and emerging-market deployment model.
  • icometrix: Brain MRI AI vendor with FDA-cleared and CE-marked modules for multiple sclerosis and dementia; adjacent neuro-imaging focus with similar clinical evidence-based GTM and pharma services motion.
  • Riverain Technologies: AI vendor specializing in chest CT and X-ray, including ClearRead CT for lung nodule and fibrosis detection; overlaps with Brainomix e-Lung in lung imaging AI.

Broad incumbents

  • Nanox: Broad medical imaging and AI platform (incorporating Zebra Medical Vision assets) selling multi-disease AI algorithms including stroke and lung; broader and less specialized than Brainomix but addresses the same hospital customers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Brainomix social profiles

Digital presence

Brainomix compliance and trust

Trust signal

Compliance3 records

Brainomix financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Brainomix leadership team

Management profile

Number of profiles

Profiles17 records

Brainomix subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Brainomix funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Brainomix M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Brainomix

What does Brainomix do?

Brainomix develops and sells AI-powered medical imaging software (the Brainomix 360 platform) that automates analysis of CT, CTA, CTP, and MRI scans for acute stroke assessment, pulmonary fibrosis detection, and solid tumor evaluation. The software is licensed to hospitals and healthcare systems as CE-marked Class IIa and FDA-cleared medical devices, with separate modules (e-ASPECTS, e-CTA, e-CTP, e-MRI, Triage Stroke, Triage LVO) available individually or as integrated packages. The company also provides clinical trial imaging biomarker services and Core Lab analytics to pharmaceutical companies for drug development.

Is Brainomix a public or private company?

Brainomix is a private company. It is classified as venture growth investor backed and is currently operating.

When was Brainomix founded?

Brainomix was founded in 2010. It employs 51 to 100 people.

Where is Brainomix based?

Brainomix is headquartered in Oxford, United Kingdom, in the Europe region.

How does Brainomix make money?

Three revenue lines are on record. Healthcare Software Licensing is the primary driver. The others are clinical Trial Imaging Services and professional Services & Training.

Who are Brainomix's main competitors?

Direct peers on record are RapidAI, Viz.ai, Avicenna.AI, Nico.lab and Ischemaview. Emerging players are Aidoc, Qure.ai, icometrix and Riverain Technologies. Nanox is listed as a broad incumbent.

Does Brainomix have an API?

No public API is recorded for Brainomix.

What industry is Brainomix in?

Brainomix's product category is AI Medical Imaging Software. Its primary akta.pro industry code is HDAAAEAH, Medical Imaging AI, with a secondary code of HLACANAG, SaMD – Imaging & Signal Analysis (AI/ML). Its NAICS code is 54169 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
In VivoBrainomix Says Biomarker Qualification Is Next Step For Its FDA-Cleared Lung AI SoftwareBrainomix's FDA-cleared e-Lung and UCLA's algorithm both detected nintedanib's benefit over placebo in a 474-patient INBUILD substudy. Baseline CT scores predicted faster FVC decline, and e-Lung's week-24 reticulovascular score predicted later mortality. FVC remains regulators' preferred primary endpoint.In VivoBrainomix Pitches Quantitative CT To Fibrosis Trial Sponsors As Boehringer Partnership DeepensBrainomix is pitching its quantitative CT software to fibrosis trial sponsors, claiming it could replace forced vital capacity as a regulatory standard. The company says higher baseline scores flag placebo patients with faster FVC decline, and new INBUILD trial data supports the approach.The Pharma LetterPost-hoc analysis suggests CT imaging could select stroke patients for Remedy’s CiraraBrainomix and Remedy Pharmaceuticals presented an exploratory post-hoc analysis of the Phase III CHARM trial at the World Stroke Conference in Seoul. The analysis suggests automated analysis of non-contrast CT scans could identify patients with large hemispheric infarction more likely to benefit from Cirara.PR NewswireBrainomix AI Imaging Analysis of Phase 3 CHARM Trial Identifies Promising Treatment Signals in Severe Stroke PatientsBrainomix and Remedy Pharmaceuticals presented post-hoc analysis of the Phase 3 CHARM trial at the World Stroke Conference, using AI to measure infarct volume on non-contrast CT. In 362 patients, CIRARA showed borderline benefit, but in 191 with core volume below 125 mL, it significantly improved functional outcomes. The findings support further evaluation of CIRARA in selected patients with large hemispheric infarction.PR NewswireBrainomix Multicenter Study Demonstrates Potential of Quantitative CT for Earlier Detection of Progressive Pulmonary Fibrosis (PPF)A multicenter study published in The Annals of the American Thoracic Society found that quantitative CT measures identified radiological progression of pulmonary fibrosis up to 28 months earlier than clinical diagnosis. The analysis linked a high baseline weighted reticulovascular score to increased PPF risk and a 1.5% change in total disease extent to increased mortality. Brainomix and Boehringer Ingelheim are continuing their collaboration through PROGRESS-PPF.PR NewswireBrainomix and Pulmonary Fibrosis Foundation Partner to Bring Patient Perspectives to AI-Powered Pulmonary Fibrosis CareBrainomix and the Pulmonary Fibrosis Foundation announced a partnership to explore how AI-powered CT analysis can support patient understanding and shared treatment decisions. The initiative will examine patient perspectives on e-Lung quantitative CT metrics and their value in clinician-patient conversations. It is part of the PROGRESS-PPF research initiative with Boehringer Ingelheim.Medical Device NetworkBrainomix’s e-Lung shows progression and treatment response in Phase III trialBrainomix reported Phase III trial data showing its e-Lung AI imaging tool detected antifibrotic treatment effects in 474 patients with progressive pulmonary fibrosis. The analysis found nintedanib significantly reduced disease extent and reticulovascular scores, and higher baseline CT measures correlated with faster FVC decline. The company suggests quantitative CT could accelerate new treatment development.YahooBrainomix’s e-Lung shows progression and treatment response in Phase III trialBrainomix presented Phase III trial data showing its e-Lung AI imaging tool measured antifibrotic treatment effects in 474 patients with progressive pulmonary fibrosis. The analysis found nintedanib significantly impacted e-Lung measures, and higher baseline disease extent correlated with faster FVC decline. The company sees this as potential to accelerate new treatment development.YahooBrainomix’s e-Lung shows progression and treatment response in Phase III trialBrainomix's e-Lung AI tool predicted disease progression and treatment response in a Phase III study of 474 patients with progressive pulmonary fibrosis. Antifibrotic treatment nintedanib significantly impacted e-Lung measures, and higher baseline CT measures correlated with faster FVC decline. The findings support quantitative CT as an objective biomarker for clinical trials.PR NewswireBrainomix Announces New Phase III INBUILD® Data Highlighting Potential of Quantitative CT to Predict Disease Progression and Assess Treatment Response in Progressive Pulmonary FibrosisBrainomix announced new data from a Phase III INBUILD HRCT sub-study of 474 patients with progressive pulmonary fibrosis, published in AJRCCM. Quantitative CT measures using Brainomix e-Lung were sensitive to nintedanib effects and associated with FVC decline, supporting qCT as a biomarker for clinical trials.